A Prospective Observational Cohort Study to Develop a Predictive Model of Taxane-Induced Peripheral Neuropathy in Cancer Patients
Treatment Effects on Development of Chemotherapy-Induced Peripheral Neuropathy in Patients With Cancer (lung, breast, ovarian)
Sponsor: Southwest Oncology Group
Enrolling: Male and Female Patients
IRB Number: AAAS3544
U.S. Govt. ID: NCT03939481
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to try to learn how certain risk factors, such as age, gender, pre-existing conditions, the type of treatment you get for your cancer, and the amount of cancer drugs in your body affect whether you develop the nerve disorder and how bad your symptoms will be. There will be about 1,000 people taking part in this study.
This study is closed
Meghna Trivedi, MD
Do You Qualify?
Do you have stage I, II, or III primary non-small cell lung, primary breast, or primary ovarian cancer? Yes No
Are you 18 years of age or older? Yes No
Are you planning to start treatment with a taxane-based chemotherapy? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator